Arunjyoti Bio Ventures Ltd

Arunjyoti Bio Ventures Limited, a micro-cap non-banking financial company with a market capitalisation of ₹133.00 crores, is navigating challenging waters as the company transitions from its historical co-packing operations to financial services. Trading at ₹7.30 per share, the stock has declined 49.66% over the past year, significantly underperforming the Sensex's 8.49% gain during the same period. With a "Very Expensive" valuation grade and deteriorating financial trends, the company faces mounting pressure to demonstrate sustainable profitability and operational clarity.

Arunjyoti Bio Ventures Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about sustained bearish momentum in the near to medium term.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 January 2026, providing investors with the latest insights into its performance and valuation.

Arunjyoti Bio Ventures Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Arunjyoti Bio Ventures has captured market attention with extraordinary buying interest, registering a 4.93% gain today and hitting the upper circuit with only buy orders in the queue. This remarkable momentum highlights a potential multi-day circuit scenario, underscoring the stock's strong demand despite broader market fluctuations.

Arunjyoti Bio, a microcap player in the Non Banking Financial Company (NBFC) sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and valuation metrics. This shift highlights the evolving investor perspective on the company’s fundamentals and market positioning.

Arunjyoti Bio Ventures Ltd has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. This rare market phenomenon highlights intense demand and the absence of sellers, signalling a potential multi-day circuit scenario for the Non Banking Financial Company (NBFC) stock.

Arunjyoti Bio Ventures Ltd has witnessed extraordinary buying momentum today, hitting the upper circuit with only buy orders in the queue. This rare market phenomenon highlights intense demand for the stock, with no sellers willing to part with shares, signalling a potential multi-day circuit scenario.

Arunjyoti Bio Ventures has witnessed extraordinary buying momentum today, with the stock hitting the upper circuit and an exclusive queue of buy orders dominating the market. This rare scenario, marked by the absence of sellers, signals a potential multi-day circuit phenomenon that has captured investor attention.

Arunjyoti Bio Ventures Ltd is currently experiencing severe selling pressure, with the stock registering a sharp decline and no buying interest visible on the trading floor. The company’s shares have been on a persistent downward trajectory, reflecting distress signals that have caught the attention of market participants and analysts alike.

Arunjyoti Bio Ventures Ltd is currently experiencing severe selling pressure, with the stock registering a lower circuit and an absence of buyers on the order book. The company’s shares have been on a persistent downward trajectory, reflecting distress selling signals and a challenging market environment for this Non Banking Financial Company (NBFC).

Arunjyoti Bio Ventures Ltd is currently experiencing severe selling pressure, with the stock registering a sharp decline of 4.9% today and showing no buying interest. This persistent downtrend is underscored by a 15-day consecutive fall, signalling distress selling within the Non Banking Financial Company (NBFC) sector.

Arunjyoti Bio Ventures Ltd is experiencing severe selling pressure with no buyers present, resulting in a sharp decline in its share price. The stock has recorded losses for 14 consecutive trading sessions, reflecting distress selling signals and a challenging market environment for this Non Banking Financial Company (NBFC).

Arunjyoti Bio Ventures Ltd is experiencing severe selling pressure, with the stock registering a decline of 4.97% today and exhibiting a complete absence of buyers. This persistent downtrend, marked by thirteen consecutive days of losses, signals distress selling within the Non Banking Financial Company (NBFC) sector.

Arunjyoti Bio Ventures Ltd has encountered significant selling pressure, with the stock registering a sharp decline and exhibiting a complete absence of buyers on the trading day. The company’s shares have recorded a continuous downward trajectory over the past twelve sessions, signalling distress selling within the Non Banking Financial Company (NBFC) sector.

Arunjyoti Bio Ventures Ltd is currently experiencing significant selling pressure, with the stock registering a sharp decline of 4.92% today and showing no buying interest. This persistent downward trend, marked by eleven consecutive days of losses, signals distress selling and heightened market caution towards the company within the Non Banking Financial Company (NBFC) sector.

Arunjyoti Bio Ventures Ltd is currently experiencing significant selling pressure, with only sell orders present in the queue. The stock has recorded a continuous decline over the past ten trading sessions, signalling distress among investors and a lack of buying interest at prevailing levels.